Trial 5O-14-1


A Prospective, Multicenter, Open-Label, Centrally Allocated, Active-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety Of Masitinib in Combination with Gemcitabine versus Gemcitabine alone in Advanced/Metastatic Epithelial Ovarian Cancer Patients in Second Line Being Refractory to First Line Platinum Treatment or in Third Line

Type: Treatment
Phase: Phase II/III
Status: Not Open (Closed)
Treatments: Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Koji Matsuo, M.D.
Other Trial Staff:  Grace Facio, R.N., Marissa Aldana, D.M., Yvonne Flores, D.M., Yanli Wang, D.M., Kristy Watkins, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.